BR9811821A - 2-acilaminopropanaminas como antagonistas de receptores de taquicinina - Google Patents

2-acilaminopropanaminas como antagonistas de receptores de taquicinina

Info

Publication number
BR9811821A
BR9811821A BR9811821-8A BR9811821A BR9811821A BR 9811821 A BR9811821 A BR 9811821A BR 9811821 A BR9811821 A BR 9811821A BR 9811821 A BR9811821 A BR 9811821A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
acylaminopropanamines
tachykinin receptor
acylaminopropanamine
tachycinin
Prior art date
Application number
BR9811821-8A
Other languages
English (en)
Inventor
James Erwin Fritz
Philip Arthur Hipskind
Stephen Warren Kaldor
Karen Lynn Lobb
James Arthur Nixon
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9811821A publication Critical patent/BR9811821A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)

Abstract

Patente de Invenção: <B>"2-ACILAMINOPROPANAMINAS COMO ANTAGONISTAS DE RECEPTORES DE TAQUICININA"<D>. São revelados antagonistas de receptores de taquicininas do tipo 2-acilaminopropanamina não-peptídica que são úteis no tratamento de várias condições, incluindo a doença de Alzheimer, e composições farmacêuticas contendo tais compostos.
BR9811821-8A 1997-08-06 1998-08-06 2-acilaminopropanaminas como antagonistas de receptores de taquicinina BR9811821A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5499797P 1997-08-06 1997-08-06
PCT/US1998/016333 WO1999007677A1 (en) 1997-08-06 1998-08-06 2-acylaminopropanamines as tachykinin receptor antagonists

Publications (1)

Publication Number Publication Date
BR9811821A true BR9811821A (pt) 2000-08-15

Family

ID=21994906

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811821-8A BR9811821A (pt) 1997-08-06 1998-08-06 2-acilaminopropanaminas como antagonistas de receptores de taquicinina

Country Status (17)

Country Link
US (1) US6358994B1 (pt)
EP (1) EP1005454A4 (pt)
JP (1) JP2001512715A (pt)
KR (1) KR20010022581A (pt)
CN (1) CN1272842A (pt)
AU (1) AU8693398A (pt)
BR (1) BR9811821A (pt)
CA (1) CA2298701A1 (pt)
EA (1) EA200000198A1 (pt)
HR (1) HRP20000065A2 (pt)
HU (1) HUP0002929A3 (pt)
ID (1) ID24468A (pt)
IL (1) IL134301A0 (pt)
NO (1) NO20000519L (pt)
PL (1) PL338453A1 (pt)
TR (1) TR200000291T2 (pt)
WO (1) WO1999007677A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8692698A (en) * 1997-08-06 1999-03-01 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
KR100599134B1 (ko) * 2001-04-23 2006-07-12 에프. 호프만-라 로슈 아게 양성 전립선 비대증에 대한 ｎｋ-1 수용체 길항물질의 용도
DE60321907D1 (de) * 2002-04-26 2008-08-14 Lilly Co Eli Tachykininrezeptorantagonisten
MY141559A (en) 2002-04-26 2010-05-14 Lilly Co Eli Triazole derivatives as tachykinin receptor antagonists
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2613068A1 (en) * 2005-06-30 2007-01-11 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
WO2011104307A2 (en) * 2010-02-25 2011-09-01 Graffinity Pharmaceuticals Gmbh Ligands for antibody purification by affinity chromatography
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
US5278316A (en) * 1989-06-29 1994-01-11 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives
EP0916346A3 (en) 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
WO1994001402A1 (en) * 1992-07-13 1994-01-20 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
EP0655055B1 (en) 1992-08-13 2000-11-29 Warner-Lambert Company Tachykinin antagonists
WO1994010167A1 (en) 1992-10-30 1994-05-11 Merck Sharp & Dohme Limited Tachykinin antagonists
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US5491140A (en) 1994-06-30 1996-02-13 Eli Lilly And Company Naphthyl tachykinin receptor antagonists to treat physiological conditions
AU688072B2 (en) * 1994-07-12 1998-03-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists

Also Published As

Publication number Publication date
US6358994B1 (en) 2002-03-19
IL134301A0 (en) 2001-04-30
HUP0002929A3 (en) 2002-01-28
EA200000198A1 (ru) 2000-10-30
EP1005454A4 (en) 2003-01-15
TR200000291T2 (tr) 2000-07-21
JP2001512715A (ja) 2001-08-28
HUP0002929A2 (hu) 2001-10-28
NO20000519L (no) 2000-03-31
PL338453A1 (en) 2000-11-06
CA2298701A1 (en) 1999-02-18
EP1005454A1 (en) 2000-06-07
AU8693398A (en) 1999-03-01
KR20010022581A (ko) 2001-03-26
WO1999007677A1 (en) 1999-02-18
ID24468A (id) 2000-07-20
HRP20000065A2 (en) 2001-04-30
CN1272842A (zh) 2000-11-08
NO20000519D0 (no) 2000-02-01

Similar Documents

Publication Publication Date Title
BR0015963A (pt) Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
DK0729468T3 (da) Ikke-peptid tachykinin-receptor-antagonister
BRPI0413922A (pt) xantinas de 8-heteroarila substituìda
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
ITRM960810A0 (it) Composizioni farmaceutiche contenenti ciclosporine o macrolidi
BR9902086A (pt) Formulações farmacêuticas.
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
BR9911724A (pt) Ciclosporina que tem um perfil de atividade melhorado
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
SE9802729D0 (sv) Novel Compounds
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
BG105256A (en) Muscarinic agonists and antagonists
TR199801268T2 (xx) Ta�ikinin antagonistleri olarak 3-Azetidinilalkilpiperidinler veya pirolidinler.
MA26547A1 (fr) Composes nouveaux, antagonistes des recepteurs de vitronectine, et compositions pharmaceutiques les contenant.
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
BR0213574A (pt) Compostos básicos lineares apresentando atividade antagonista do nk-2 e formulações contendo os mesmos
BR9810433A (pt) Composições anti-helmìnticas
DE69831737D1 (de) Neurotrypsin
BR9814188A (pt) &#34;agonistas de 5-ht1f&#34;
BR9807312A (pt) Derivados de (4-piperidinil)-1h-2-benzopirano úteis como agentes antipsicóticos
BR9811819A (pt) 2-acilaminopropanaminas como antagonistas receptores de taquicinina

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]